Literature DB >> 12484006

[A case of postoperative hepatic metastasis from gastric cancer responding to hepatic arterial infusion chemotherapy of paclitaxel].

Shigeo Matsui1, Takeshi Tono, Takashi Iwazawa, Masakatsu Kinuta, Hiroshi Yano, Yoshiaki Nakano, Toshiyuki Kanoh, Kazuyuki Okada, Tadafumi Asaoka, Mitsunobu Imasato, Jun Okamura, Takushi Monden.   

Abstract

A 70-year-old man underwent total gastrectomy for advanced gastric cancer in January 2000. He was treated with UFT of 300 mg/day after surgery. In December 2000, liver metastasis was detected. In January 2001, treatment was switched to oral administration of TS-1 at 100 mg/day. In April 2001, there were no extrahepatic lesions. However, the metastatic liver focus showed progression of the disease (PD). TS-1 was discontinued. In May 2001, a hepatic arterial injection reservoir was inserted. Thereafter, arterial injection chemotherapy with 5-FU was administered. However, in November, liver dysfunction was exacerbated, and computed tomography (CT) revealed PD. Therefore, in December, the above chemotherapy was switched to arterial injection of paclitaxel at 100 mg, which was administered once a week for 3 weeks and discontinued for the subsequent week. In March 2002, hepatopathy had subsided at the end of the 4th course, the performance status (PS) improved and CT revealed a minor response. In June 2002, the condition deteriorated to PD. However, there were no side effects other than alopecia. During the administration period, treatment at the outpatient clinic could be safely performed. These findings suggest that hepatic arterial injection therapy with paclitaxel for liver metastasis after surgery for gastric cancer is a useful second line for 5-FU-resistant patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12484006

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement.

Authors:  Apostolia M Tsimberidou; Katherine Letourneau; Siqing Fu; David Hong; Aung Naing; Jennifer Wheler; Cynthia Uehara; Stephen E McRae; Sijin Wen; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-13       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.